SG11201607795UA - Inos-inhibitory compositions and their use as breast cancer therapeutics - Google Patents
Inos-inhibitory compositions and their use as breast cancer therapeuticsInfo
- Publication number
- SG11201607795UA SG11201607795UA SG11201607795UA SG11201607795UA SG11201607795UA SG 11201607795U A SG11201607795U A SG 11201607795UA SG 11201607795U A SG11201607795U A SG 11201607795UA SG 11201607795U A SG11201607795U A SG 11201607795UA SG 11201607795U A SG11201607795U A SG 11201607795UA
- Authority
- SG
- Singapore
- Prior art keywords
- inos
- breast cancer
- cancer therapeutics
- inhibitory compositions
- inhibitory
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 239000012830 cancer therapeutic Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461976956P | 2014-04-08 | 2014-04-08 | |
PCT/US2015/025009 WO2015157471A1 (en) | 2014-04-08 | 2015-04-08 | Inos-inhibitory compositions and their use as breast cancer therapeutics |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201607795UA true SG11201607795UA (en) | 2016-10-28 |
Family
ID=53008865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201607795UA SG11201607795UA (en) | 2014-04-08 | 2015-04-08 | Inos-inhibitory compositions and their use as breast cancer therapeutics |
Country Status (9)
Country | Link |
---|---|
US (4) | US20170020835A1 (zh) |
EP (2) | EP3129015B1 (zh) |
JP (4) | JP2017515800A (zh) |
KR (1) | KR20160143775A (zh) |
CN (1) | CN106572988B (zh) |
AU (1) | AU2015243537B2 (zh) |
CA (1) | CA2979530C (zh) |
SG (1) | SG11201607795UA (zh) |
WO (1) | WO2015157471A1 (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2445932B1 (en) | 2009-06-26 | 2018-02-28 | Soricimed Biopharma Inc. | Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery |
SG11201607795UA (en) * | 2014-04-08 | 2016-10-28 | Methodist Hospital | Inos-inhibitory compositions and their use as breast cancer therapeutics |
TWI663984B (zh) * | 2014-10-24 | 2019-07-01 | 朗齊生物醫學股份有限公司 | 神經疾病用藥臨床新應用 |
TW202408592A (zh) | 2016-03-02 | 2024-03-01 | 日商衛材R&D企管股份有限公司 | 基於艾日布林之抗體-藥物結合物及使用方法 |
WO2017163243A1 (en) * | 2016-03-22 | 2017-09-28 | Hadasit Medical Research Services And Development Ltd. | Modulation of calcium channel splice variant in cancer therapy |
WO2018071837A1 (en) * | 2016-10-14 | 2018-04-19 | Baylor College Of Medicine | Radiofrequency field hyperthermia and solid tumor immunomodulation |
WO2019008516A2 (en) * | 2017-07-03 | 2019-01-10 | Menri Group Ltd. | TREATMENT OF CANCER WITH DIHYDROPYRIDINES |
JP2020537636A (ja) * | 2017-09-22 | 2020-12-24 | マンセル、ジョン | 敗血症関連障害の処置のための組成物及び方法 |
US20200384069A1 (en) * | 2017-12-01 | 2020-12-10 | Soricimed Biopharma Inc. | Trpv6 inhibitors and combination therapies for treating cancers |
WO2019147089A1 (ko) * | 2018-01-26 | 2019-08-01 | 재단법인 대구경북첨단의료산업진흥재단 | 칼슘 채널 억제제 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
KR102212699B1 (ko) | 2019-08-12 | 2021-02-05 | 한국원자력의학원 | 유방암 예방 또는 치료용 조성물 |
CN113897357A (zh) * | 2020-07-06 | 2022-01-07 | 北京大学 | Twist1基因编辑***及其在制备治疗三阴性乳腺癌的产品中的应用 |
WO2024063566A1 (ko) * | 2022-09-22 | 2024-03-28 | (의) 삼성의료재단 | 종양 혈관 파괴용 약학 조성물 |
WO2024063569A1 (ko) * | 2022-09-22 | 2024-03-28 | (의) 삼성의료재단 | 종양 혈관 파괴용 약학 조성물 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3121152A1 (de) * | 1981-05-22 | 1982-12-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie" |
US4658957A (en) * | 1985-01-28 | 1987-04-21 | Abbott Laboratories | Utility tray |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
US5747532A (en) | 1995-11-21 | 1998-05-05 | Medinox, Inc. | Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor |
GB9625895D0 (en) | 1996-12-13 | 1997-01-29 | Riley Patrick A | Novel compound useful as therapeutic agents and assay reagents |
CA2295098A1 (en) | 1997-06-30 | 1999-01-07 | Allergan Sales, Inc. | Calcium blockers to treat proliferative vitreoretinopathy |
US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
US8431117B2 (en) | 1999-08-30 | 2013-04-30 | David S Terman | Sickled erythrocytes with anti-tumor agents induce tumor vaso-occlusion and tumoricidal effects |
GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
US7678391B2 (en) * | 2000-04-26 | 2010-03-16 | Queen's University At Kingston | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
CA2478145A1 (en) * | 2002-03-06 | 2003-09-12 | Cellegy Pharmaceuticals, Inc. | Formulations and methods of using nitric oxide mimetics in cancer treatment |
US20050271596A1 (en) | 2002-10-25 | 2005-12-08 | Foamix Ltd. | Vasoactive kit and composition and uses thereof |
WO2005082407A1 (en) | 2003-11-03 | 2005-09-09 | Musc Foundation For Research Development | Use of quercetin and resveratrol to treat and prevent oral cancer |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
JP2008521908A (ja) | 2004-12-01 | 2008-06-26 | カリプシス・インコーポレーテッド | 誘導型一酸化窒素シンターゼ阻害剤 |
JP2008537538A (ja) * | 2005-02-11 | 2008-09-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Vegf拮抗剤及び降圧剤の治療的組み合わせ |
TW200803855A (en) | 2006-02-24 | 2008-01-16 | Kalypsys Inc | Quinolones useful as inducible nitric oxide synthase inhibitors |
WO2007101213A2 (en) | 2006-02-28 | 2007-09-07 | Kalypsys, Inc. | Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors |
WO2007123777A2 (en) * | 2006-03-30 | 2007-11-01 | Duke University | Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses |
US20080069904A1 (en) | 2006-07-18 | 2008-03-20 | Oronsky Bryan T | Inhibition of angiogenesis through nitric oxide tachyphylaxis |
WO2008046459A1 (en) | 2006-10-16 | 2008-04-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Treatment of chemotherapy- or radiotherapy-resistant tumors using an l1 interfering molecule |
WO2008103615A1 (en) | 2007-02-21 | 2008-08-28 | Kalypsys, Inc. | Isoquinolines useful as inducible nitric oxide synthase inhibitors |
WO2009029592A1 (en) | 2007-08-27 | 2009-03-05 | Kalypsys, Inc. | Heterobicyclic-substituted quinolones useful as nitric oxide synthase inhibitors |
EP2342175B1 (en) * | 2008-09-24 | 2015-05-27 | Nitrogenix Inc. | Nitric oxide releasing amino acid ester compound, composition and method of use |
WO2011032000A2 (en) * | 2009-09-10 | 2011-03-17 | New York University | Method for protection of antimicrobial and anticancer drugs from inactivation by nitric oxide |
JP5605511B2 (ja) * | 2011-08-02 | 2014-10-15 | アステラス製薬株式会社 | 薬剤の併用による癌治療方法 |
SG11201607795UA (en) * | 2014-04-08 | 2016-10-28 | Methodist Hospital | Inos-inhibitory compositions and their use as breast cancer therapeutics |
-
2015
- 2015-04-08 SG SG11201607795UA patent/SG11201607795UA/en unknown
- 2015-04-08 KR KR1020167031184A patent/KR20160143775A/ko not_active Application Discontinuation
- 2015-04-08 AU AU2015243537A patent/AU2015243537B2/en active Active
- 2015-04-08 CA CA2979530A patent/CA2979530C/en active Active
- 2015-04-08 CN CN201580018474.1A patent/CN106572988B/zh active Active
- 2015-04-08 EP EP15719050.5A patent/EP3129015B1/en active Active
- 2015-04-08 JP JP2016561279A patent/JP2017515800A/ja not_active Withdrawn
- 2015-04-08 EP EP21184191.1A patent/EP3967303A1/en active Pending
- 2015-04-08 WO PCT/US2015/025009 patent/WO2015157471A1/en active Application Filing
-
2016
- 2016-10-10 US US15/289,871 patent/US20170020835A1/en not_active Abandoned
-
2017
- 2017-04-12 US US15/486,183 patent/US10420838B2/en active Active
-
2019
- 2019-09-24 US US16/581,746 patent/US20200016265A1/en not_active Abandoned
- 2019-09-24 US US16/581,630 patent/US11357850B2/en active Active
-
2020
- 2020-06-08 JP JP2020099268A patent/JP2020128445A/ja active Pending
- 2020-06-08 JP JP2020099269A patent/JP2020128446A/ja active Pending
-
2022
- 2022-08-22 JP JP2022131687A patent/JP2022159552A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2020128445A (ja) | 2020-08-27 |
AU2015243537A1 (en) | 2016-10-06 |
US20200016265A1 (en) | 2020-01-16 |
EP3129015A1 (en) | 2017-02-15 |
US10420838B2 (en) | 2019-09-24 |
JP2020128446A (ja) | 2020-08-27 |
KR20160143775A (ko) | 2016-12-14 |
CN106572988A (zh) | 2017-04-19 |
CN106572988B (zh) | 2022-04-08 |
CA2979530C (en) | 2023-10-03 |
US20170020835A1 (en) | 2017-01-26 |
US20200306371A1 (en) | 2020-10-01 |
US11357850B2 (en) | 2022-06-14 |
EP3129015B1 (en) | 2021-07-14 |
JP2017515800A (ja) | 2017-06-15 |
US20170224814A1 (en) | 2017-08-10 |
EP3967303A1 (en) | 2022-03-16 |
JP2022159552A (ja) | 2022-10-17 |
WO2015157471A1 (en) | 2015-10-15 |
AU2015243537B2 (en) | 2020-10-22 |
CA2979530A1 (en) | 2015-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201607795UA (en) | Inos-inhibitory compositions and their use as breast cancer therapeutics | |
GB201411197D0 (en) | Composition and use thereof | |
HK1232137A1 (zh) | 治療化合物和組合物 | |
IL250568B (en) | Anti-methanogenic preparations and their uses | |
PT3015526T (pt) | Composição à base de hidrofluoroolefina e sua utilização | |
IL276733A (en) | Use of Aribolin in cancer treatment | |
EP3186393A4 (en) | Methods and compositions related to prostate cancer therapeutics | |
ZA201701909B (en) | Trichoderma compositions and methods of use | |
IL250582B (en) | Compositions and methods for early screening of medical components | |
EP3008124A4 (en) | STRENGTH COMPOSITIONS AND USE THEREOF | |
HK1231426A1 (zh) | 皮膚增白美容組合物 | |
IL255560A (en) | Macrophinocytosis in cancer | |
GB2537548B (en) | Set-delayed cement compositions comprising pumice and associated methods | |
IL251238B (en) | Mineral-based compounds and their uses | |
GB201411196D0 (en) | Composition and use thereof | |
IL248126A0 (en) | Combinations of cancer treatments | |
GB201408233D0 (en) | Use of polyanionic composition | |
GB201522573D0 (en) | Cancer therapeutics | |
GB201503273D0 (en) | Cancer therapeutics | |
GB201404391D0 (en) | Novel compositions having use in therapy | |
GB201500760D0 (en) | Cancer therapeutics | |
GB201502816D0 (en) | Novel Compositions having use in therapy | |
ZA201403006B (en) | Composition for use in treatment of cancer | |
GB201418410D0 (en) | use of compositions of matter | |
GB201410695D0 (en) | Uses of oligouronates in cancer treatment |